Abstract:Advancements in sequencing technologies and bioinformatics algorithms have expanded our ability to identify tumor-specific somatic mutation-derived antigens (neoantigens). While recent studies have shown neoantigens to be compelling targets for cancer immunotherapy due to their foreign nature and high immunogenicity, the need for increasingly accurate and cost-effective approaches to rapidly identify neoantigens remains a challenging task, but essential for successful cancer immunotherapy. Currently, gene expression analysis and algorithms for variant calling can be used to generate lists of mutational profiles across patients, but more care is needed to curate these lists and prioritize the candidate neoantigens most capable of inducing an immune response. A growing amount of evidence suggests that only a handful of somatic mutations predicted by mutational profiling approaches act as immunogenic neoantigens. Hence, unbiased screening of all candidate neoantigens predicted by Whole Genome Sequencing/Whole Exome Sequencing may be necessary to more comprehensively access the full spectrum of immunogenic neoepitopes. Once putative cancer neoantigens are identified, one of the largest bottlenecks in translating these neoantigens into actionable targets for cell-based therapies is identifying the cognate T cell receptors (TCRs) capable of recognizing these neoantigens. While many TCR-directed screening and validation assays have utilized bulk samples in the past, there has been a recent surge in the number of single-cell assays that provide a more granular understanding of the factors governing TCR-pMHC interactions. The goal of this review is to provide an overview of existing strategies to identify candidate neoantigens using genomics-based approaches and methods for assessing neoantigen immunogenicity. Additionally, applications, prospects, and limitations of some of the current single-cell technologies will be discussed. Finally, we will briefly summarize some of the recent models that have been used to predict TCR antigen specificity and analyze the TCR receptor repertoire.

Antigen discovery for the development of cancer immunotherapy

Identification of tumor antigens with immunopeptidomics

Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy

Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process

Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery

The landscape of T cell antigens for cancer immunotherapy

Mapping the cancer surface proteome in search of target antigens for immunotherapy

Immunopeptidomics in the cancer immunotherapy era

Melanoma antigens recognized by T cells and their use for immunotherapy

Antigen processing and presentation in cancer immunotherapy

Bioinformatics for cancer immunotherapy target discovery

Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

Uncovering the modified immunopeptidome reveals insights into principles of PTM-driven antigenicity

Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma

Caatlas: an Immunopeptidome Atlas of Human Cancer.

Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy

Harnessing microbial antigens as cancer antigens: a promising avenue for cancer immunotherapy

A proteogenomic approach to target neoantigens in solid tumors

Human Tumor Antigens and Cancer Immunotherapy

Contemplating immunopeptidomes to better predict them